Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p>Hong Kong Exchanges and Clearing Limited (HKEX) has decided to modify its rules to allow "pre-commercial" biopharmaceutical (aka biotechnology) companies to list on the exchange. This move reflects the progress of China's biopharmaceutical industry and offers new competition to Taipei and New York as listing venues. Some companies will avail themselves of this opportunity, but we think that a majority of 2018's listings will choose New York (NASDAQ/NYSE).</p>

Hong Kong Exchanges and Clearing Limited (HKEX) has decided to modify its rules to allow "pre-commercial" biopharmaceutical (aka biotechnology) companies to list on the exchange. This move reflects the progress of China's biopharmaceutical industry and offers new competition to Taipei and New York as listing venues. Some companies will avail themselves of this opportunity, but we think that a majority of 2018's listings will choose New York (NASDAQ/NYSE).

"Exchange Arbitrage" For Early-Stage Biotech!

Taiwan

Taiwan Liposome Company, Ltd. operates as a biopharmaceutical company. The Company provides drug delivery technology development, new drugs researches, and other services. Taiwan Liposome also produces lipid based formulations, parenteral drugs, and other products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Taiwan Liposome (4152 TT)

"Exchange Arbitrage" For Early-Stage Biotech!

Hong Kong Exchanges and Clearing Limited (HKEX) has decided to modify its rules to allow "pre-commercial" biopharmaceutical (aka biotechnology)...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)